Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date

Group 1 - The article discusses Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) and its flagship candidate, cosibelimab, which has the potential for dual approval in locally advanced and metastatic conditions [1] - The author emphasizes the importance of innovative companies in the biotech sector that are developing breakthrough therapies and pharmaceuticals with catalysts for potential acquisitions [1] Group 2 - The article does not provide any financial data or performance metrics related to Checkpoint Therapeutics or its products [2][3]